Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT400 in CD20+ B-cell Non Hodgkin's Lymphoma
NCT02206308Phase 1Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- May 2012
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of ripertamab in B-cell non-Hodgkin lymphoma, sponsored by Sinocelltech Group Limited. Primary endpoint: Number of participants with infusion-related reaction and with drug-related adverse events up to 27 weeks. Started May 2012; status: completed.
02
Drugs
ripertamab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02206308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206308.